(Q36108605)

12 August 2017

1 reference

title

Molecularly targeted therapies for breast cancer (English)

1 reference

12 August 2017

Timothy J Hobday

1

1 reference

12 August 2017

Edith A Perez

series ordinal

2

1 reference

12 August 2017

publication date

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

12

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

73-81

1 reference

12 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

Proteasome inhibitors as new anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200202

10.1177/107327480501200202

21 January 2018

Identifiers

DOI

0 references

1 reference